Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

199.60
+3.681.88%
Volume:772.26K
Turnover:154.61M
Market Cap:42.78B
PE:-22.37
High:202.02
Open:198.53
Low:198.00
Close:195.92
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:1.46
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.42
PE(LYR):-33.55

Loading ...

Revolution Medicines, Inc. : JP Morgan Raises Target Price to $227 from $205

THOMSON REUTERS
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Revolution Medicines price target raised to $227 from $205 at JPMorgan

TIPRANKS
·
Aug 08

Alphabet Reports Share Stake in SpaceX, Fervo Energy and Parabilis Medicines

Reuters
·
Aug 07

Alphabet Inc. Cuts Share Stake in Revolution Medicines Inc by 10.5% to 2.9 Mln Shares - SEC Filing

THOMSON REUTERS
·
Aug 07

Bernstein Remains a Hold on Revolution Medicines (RVMD)

TIPRANKS
·
Aug 06

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06

Wedbush Adjusts PT on Revolution Medicines to $201 From $192.10, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291

TIPRANKS
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines Q2 2026 Earnings: Daraxonrasib Advances as Spending Rises

TradingKey
·
Aug 06

Earnings Flash (RVMD) Revolution Medicines Posts Q2 Loss $3.06, vs. FactSet Est of $2.04 Loss

MT Newswires Live
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)

TIPRANKS
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Benzinga Earnings
·
Aug 06

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS
·
Aug 06

Movement Alert|Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally

Market Focus
·
Aug 05